BTIG initiates coverage of Tvardi Therapeutics with a 'Buy' rating

Summary

BTIG has initiated coverage on Tvardi Therapeutics with a ‘buy’ rating and a target price of $55, indicating a potential 108.7% upside. Tvardi is leading in the development of fibrosis disease STAT3 inhibitors, with their main drug TTI-101 showing promise in reversing lung scarring, where early trials showed improvement in over 50% of patients. Mid-term trial data expected in late 2025 may serve as a significant catalyst for the stock. The stock is up 43.5% year-to-date.Reuters Tvardi has enough cash reserves to sustain operations until the second half of 2026 and has recently completed a merger with Cara Therapeutics, supporting further development of STAT3 inhibitor TTI-101.Reuters+ 2

Impact Analysis

The event is primarily at the company level, focusing on Tvardi Therapeutics. The ‘buy’ rating from BTIG and high target price suggest strong confidence in Tvardi’s growth prospects. The merger with Cara Therapeutics provides financial stability and resources to continue developing TTI-101, a promising drug for reversing lung scarring, potentially leading to significant future revenue. BTIG’s positive outlook can boost investor confidence, potentially increasing demand and driving up the stock price. Risks include clinical trial setbacks or market competition. Investors might find opportunities in buying Tvardi’s stock due to its potential upside and participation in a promising biotech segment.Reuters+ 3